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Abstract
Background: Patients with severe burn injury experience a rapid elevation in multiple circulating pro-
inflammatory cytokines, with the levels correlating with both injury severity and outcome. Accumulations
of these cytokines in animal models have been observed in remote organs, however data are lacking
regarding early brain cytokine levels following burn injury, and the effects of estradiol on these levels. Using
an experimental animal model, we studied the acute effects of a full-thickness third degree burn on brain
levels of TNF-α, IL-1β, and IL-6 and the protective effects of acute estrogen treatment on these levels.
Additionally, the acute administration of estrogen on regulation of inflammatory and apoptotic events in
the brain following severe burn injury were studied through measuring the levels of phospho-ERK,
phospho-Akt, active caspase-3, and PARP cleavage in the placebo and estrogen treated groups.
Methods: In this study, 149 adult Sprague-Dawley male rats received 3rd degree 40% total body surface
area (TBSA) burns. Fifteen minutes following burn injury, the animals received a subcutaneous injection of
either placebo (n = 72) or 17 beta-estradiol (n = 72). Brains were harvested at 0.5, 1, 2, 4, 6, 8, 12, 18, and
24 hours after injury from the control (n = 5), placebo (n = 8/time point), and estrogen treated animals (n
= 8/time point). The brain cytokine levels were measured using the ELISA method. In addition, we assessed
the levels of phosphorylated-ERK, phosphorylated-Akt, active caspase-3, and the levels of cleaved PARP
at the 24 hour time-point using Western blot analysis.
Results: In burned rats, 17 beta-estradiol significantly decreased the levels of brain tissue TNF-α (~25%),
IL-1β (~60%), and IL-6 (~90%) when compared to the placebo group. In addition, we determined that in
the estrogen-treated rats there was an increase in the levels of phospho-ERK (p < 0.01) and Akt (p < 0.05)
at the 24 hour time-point, and that 17 beta-estradiol blocked the activation of caspase-3 (p < 0.01) and
subsequent cleavage of PARP (p < 0.05).
Conclusion: Following severe burn injury, estrogens decrease both brain inflammation and the activation
of apoptosis, represented by an increase in the levels of phospho-Akt and inhibition of caspase-3 activation
and PARP cleavage. Results from these studies will help further our understanding of how estrogens
protect the brain following burn injury, and may provide a novel, safe, and effective clinical treatment to
combat remote secondary burn injury in the brain and to preserve cognition.
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Background
Burn injuries are a significant cause of death and disability
around the world. In the United States, there are greater
than 40,000 hospital visits for burn injury annually.
Between 1995 to 2005 (National Burn Repository), there
were 126,000 admissions to hospitals for burn injury [1].
A significant incidence of multiple organ (liver, thymus,
spleen, skeletal muscle, lung, heart, and brain) dysfunc-
tion and failure has been noted in both animals and
humans, surviving the initial insult of severe burn injury.
This failure of different organ systems is thought to be, at
least in part, due to increased apoptotic cell death and
enhanced production of inflammatory cytokines such as
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α),
interleukin 1beta (IL-1β), and prostaglandins [2-4]. For
example, following burn injury there is a significant
increase in DNA damage and fragmentation in cardiac
myocytes [5]. Additionally, in the heart, thymus, and
spleen there is an increase in the levels of active caspase 3,
6, 8, and 9, which results in increased apoptotic cell death
after burn injury in rats and mice [6-9]. Following severe
burn injury, there is also an increase in signaling pathways
such as the p38 and Jnk MAPKs leading to an amplifica-
tion in cytokine production and the initiation of apopto-
sis [5,7,9,10]. With respect to the brain, previous studies
have demonstrated that the brain is one of the remote
organs subject to injurious effects following severe burn
injury [10-15]. For example, neuropsychological disor-
ders have been documented in children following burn
injury. In these children, chronic mental disability was
correlated with the size of the burn injury [12]. Addition-
ally, a retrospective clinical study found that a small per-
centage of burn patients also suffer from acute stroke [11].
In animal studies of burn injury, magnetic resonance
imaging has identified marked changes in the brain up to
3 days post-burn injury, most notably brain swelling and
lesions [14]. Over the initial 24 hour post-burn period,
rats have been found to display decreased glucose utiliza-
tion in the brain, however by week three the glucose utili-
zation returned to baseline, indicating an acute
dysregulation of glucose metabolism in the brain [16]. In
behavioral studies such animals appear to have long-term
cognitive deficits associated with a disruption in the
blood-brain barrier [17-19], increased inflammation [13],
and/or altered metabolism in the brain [10,16].
Estrogens have been shown to significantly decrease the
levels of inflammatory cytokines and improve outcomes
in animal models of burn injury. Some of estrogen's pro-
tective mechanisms of action include both maintaining
the integrity of the mitochondria and decreasing the activ-
ity of a multitude of pro-apoptotic factors [20,21]. In pre-
vious animal models of severe burn injury, estrogen
treatment resulted in a decrease in systemic and local pro-
duction of pro-inflammatory cytokines [22-24]. In these
studies, estrogen decreased the levels of oxidative stress,
inflammatory cytokines (IL-6, TNF-α), NF kappa beta
(NFκβ) signaling, and importantly maintained the histo-
logical architecture of organs such as the stomach and sig-
nificantly improved survival [22,24-28]. Since estrogens
protect the brain from oxidative insults and inflammation
in other models of acute brain injury such as stroke [29-
33], we hypothesize that, following severe burn injury, a
single dose of 17 β-estradiol would decrease inflamma-
tion in the brain, which might ultimately protect the brain
from the injurious effects of a severe remote burn.
Methods
Experimental model
A total of 149 Adult male Sprague-Dawley rats weighing
325 to 350 g were obtained from Harlan Laboratories
(Houston, TX) and housed in a University of Texas South-
western Medical Center (UT Southwestern) animal care
facility. Commercial rat chow and tap water were availa-
ble ad libitum, and rats were maintained in a constant
temperature environment with a 12-h light/dark cycle. All
experiments were performed under a protocol approved
by the UT Southwestern Institutional Animal Care and
Research Advisory Committee, and the work conformed
to all guidelines outlined in the Guide for the Care and
Use of Laboratory Animals published by the American
Physiological Society.
Burn injury and estrogen treatment
Rats were deeply anesthetized with isoflurane, secured in
a constructed template device that exposed 40% of the
total body surface area (TBSA) of the animal, and then
administered a full thickness scald burn as previously
described [34]. Briefly, the back and flank skin were
shaved, and the animal was secured into a specially
designed template. The skin that was exposed through the
template was immersed in 100°C water for 10 seconds to
produce a full thickness dermal burn over 40% of the
TBSA. This burn technique produces complete destruction
of the underlying nerve tissue, resulting in a burn injury
that should not result in pain to the subject animal. After
immersion, the rats were immediately dried, followed by
standard fluid resuscitation based on the Parkland Burn
Formula consisting of 4 ml/kg per percent burn of lactated
Ringer (LR) solution intra-peritoneally (IP), with 1/2 of
the calculated volume being given immediately after com-
pletion of the burn injury, and the other half given 8
hours post-burn. In addition to the LR, rats also received
0.1 mg/kg of IP Buprenorphine for pain control. Follow-
ing fluid resuscitation, each animal was placed in an indi-
vidual cage that rested on a heating pad. Burned rats did
not display discomfort or pain, moved freely about the
cage, and consumed food and water within 15 minutes
after recovering from isoflurane anesthesia. Control ani-
mals (n = 5) were administered sham burns, which were
treated in a manner identical to the burn treatment except
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received no study drug. Fifteen minutes following true
burn injury, the burned animals received either a subcuta-
neous dose (SQ) of 0.5 mg/kg of 17 β-estradiol (n = 72)
or an equivalent volume of placebo (vehicle, which was
corn oil) (n = 72) based on a computer-generated rand-
omization schedule. This subcutaneous delivery of 17 β-
estradiol has previously been shown to produce similar
pharmacokinetics to intravenous dosing in other animal
models, but with greater ease of delivery [35]. All investi-
gators were blinded to the treatment group of the animals.
At 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours post-burn, eight
animals from the placebo group and eight animals from
the estrogen group were sacrificed at each time point, the
brains were harvested, and total protein isolated. Control
animals were sacrificed and harvested in the same manner
at the 24 hour time point.
ELISA
The TNF-α, IL-1β, and IL-6 cytokines were measured from
the brain using the Enzyme Linked-Immuno-Sorbent
Assay (ELISA; Invitrogen, Camirillo, CA). In brief, 50 μl of
each sample and the biotinylated anti-TNF-α, IL-1β, and
IL-6 was added in duplicate to the appropriate 96-well
plate and incubated for approximately 2 hours at room-
temperature. Following the 2 hour treatment, the plates
were washed and 100 μl of the Streptavidin-HRP was
added for 30 minutes at room-temperature. After the 30
minute incubation, 100 μl of the Stabilized Chromogen
was added to each well and 100 μl of stop solution was
added to stop the reaction. The absorbance was detected
at 450 nm.
Western blot analysis
The harvested rat brains were placed in 0.5 ml of lysis
buffer in order to isolate the total protein (50 mM Tris,
pH7.4; 150 mM NaCl; 10% glycerol; 1 mM EGTA; 1 mM
Na3VO4; 5 mM ZnCl2; 100 mM NaF; 1% Triton X-100;
10 mg/mL of aprotinin; 1 mg/mL of leupeptin; and 1 mM
phenylmethylsulfonyl fluoride), then homogenized and
centrifuged for 10 minutes. Following centrifugation, the
supernatant was collected and analyzed for protein con-
centration. Protein concentrations were determined using
the Bio-Rad DC protein assay kit (based on the method of
Lowry; [36]). Total protein (100 μg) was loaded onto a
sodium dodecyl sulfate (SDS), 10% polyacrylamide gel
(PAGE) and run at 100 volts for 1 hour. After electro-
phoresis, the protein was transferred to a polyvinylidene
difluoride membrane (PVDF; 0.22 mm pore size, Bio-Rad,
Hercules, CA) and blocked for 3 hrs in a 3% bovine serum
albumin (BSA), 0.2% Tween-containing TBS (TBS-T)
solution. The membrane was subsequently probed with
the phospho-p44/42 Map Kinase (1:1000; Cell Signal-
ing), phospho Akt (1:1000; Cell Signaling), total Erk1/2
(1:1000; Cell Signaling), active caspase 3 (1:500; Sigma
Aldrich), or the poly (ADP-ribose) polymerase (PARP;
1:200, Sigma Aldrich) antibodies. Antibody binding to
the membrane was detected using a secondary antibody
(goat anti-rabbit) conjugated to horseradish peroxidase
(1:20,000; Pierce, Rockford, IL.) and visualized with the
aid of an imaging system, using enzyme-linked chemilu-
minescence (ECL; Amersham, Arlington Heights, IL). All
blots were re-probed with anti- Erk1/2 antibodies to
ensure equal loading. Densitometric analyses of the pro-
tein levels was performed to conduct statistical analyses.
Measurement of plasma 17  -estradiol levels
17 β-estradiol levels were measured from the plasma of
the control group, the placebo group, and the estrogen
group using the commercially available estradiol radioim-
munoassay kit (DSL-440, Diagnostic Systems Laborato-
ries, Webster, TX.). The assay was performed according to
the manufacturer's protocol as previously published [35].
In brief, plasma samples (100 μl) were collected and
measured in triplicate. The values were compared to the
standard curve and the lowest levels of serum 17 β-estra-
diol was approximately 5 pg/ml.
Statistics
Data obtained from no fewer than six independent ani-
mals were analyzed using the Student's t-test analysis.
Groups were considered to be significantly different if P
values < 0.05 (SPSS; Chicago, IL). The data are presented
as a bar graph depicting the mean ± SEM, using the Graph-
Pad Software (San Diego, CA).
Results
Treatment with 17  -estradiol decreases burn-induced 
inflammation in the brain
In the current study, our primary goal was to elucidate the
effect of acute estrogen administration on the levels of
inflammatory cytokines in the brain following burn
injury. To evaluate the circulating 17 β-estradiol concen-
trations of all animals in the study, we measured the
plasma 17 β-estradiol concentrations to determine the
bioavailability of our steroid hormone preparation given
SQ. We found that in those animals receiving SQ estra-
diol, there was a time-dependent increase in the levels of
circulating 17 β-estradiol concentrations ranging from
approximately 1 ng/ml to approximately 10 ng/ml. The
basal levels of estradiol in both the control and placebo
groups was approximately 20 pg/ml, and remained rela-
tively constant at all measured time points (Fig. 1).
With respect to inflammatory cytokines measured in the
rat brain tissue, at all evaluated time-points there was a
significant reduction in TNF-α levels in the 17 β-estradiol
group compared to the placebo group (*p < 0.05 at 4, 8,
12, 18, and 24 hours post-injury, and **p < 0.01 at 0.5, 1,
2, and 6 hours post-injury). Of interest, there was a near
doubling in the levels of TNF-α in both the placebo and
17 β-estradiol groups noted at the 24 hour time-point
compared to earlier time-points (Fig. 2). Analysis of IL-1βJournal of Neuroinflammation 2009, 6:30 http://www.jneuroinflammation.com/content/6/1/30
Page 4 of 10
(page number not for citation purposes)
in the rat brain tissue revealed a 12-fold average increase
in the IL-1β levels of the placebo-group compared to the
control animals at all time points, however this difference
waned significantly at twenty-four hours, where there was
only a 3-fold increase in the levels of IL-1β in the placebo
group compared with controls (Fig. 3). In the estrogen-
treated animals, the levels of IL-1β were suppressed by
approximately 50-85 percent compared with placebo-
treated animals at all time points.
Most strikingly, the IL-6 cytokine levels in the brain tissue
spiked rapidly, and continued to consistently increase
over time at all measured intervals. In contrast, 17 β-estra-
diol treatment resulted in complete elimination of the
burn-induced increase in IL-6 levels. Within the estrogen
treated group, the levels of IL-6 were similar to the control
group at all time points. Acute 17 β-estradiol treatment
significantly lowered IL-6 levels in the brain tissue com-
pared with the placebo-treated group (Fig. 4; †p < 0.001 at
8, 12, and 24 hours post-burn, and ‡p < 0.0001 at 0.5, 1,
2, 4, 6, and 18 hours post-burn).
Estrogen increases ERK and Akt signaling in the brain 
following severe burn injury in rats
Since some of estrogen's protective effects are known to be
mediated through ERK, we hypothesized that this steroid
hormone would increase the activity of ERK in order to
decrease inflammation and damage to the brain. In this
study, we analyzed the levels of phospho-ERK using West-
ern blot analysis to determine if estrogen modulates the
activity of ERK in the brain following burn injury. We
found that post-injury, estrogen treatment results in a 2.5-
fold (p < 0.01) increase in the levels of phospho-ERK2 at
Estrogen concentrations in rats following severe burn injury Figure 1
Estrogen concentrations in rats following severe 
burn injury. Using a radioimmunoassay method, we found 
that at 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours post burn there 
was a significant increase in the levels of serum estradiol in 
those animals receiving a single dose of 17 β-estradiol. 
Depicted are mean ± SEM for n = 5. † p < 0.001, and ‡ p < 
0.0001 vs. Placebo.
Estrogen decreases the local concentration of TNF-α in the  brain following severe burn injury Figure 2
Estrogen decreases the local concentration of TNF-  
in the brain following severe burn injury. Using the 
ELISA method, we found that at 0.5, 1, 2, 4, 6, 8, 12, 18, and 
24 hours post burn there was a significant decrease in the 
levels of TNF-α in those animals receiving 17 β-estradiol 
compared with the placebo group. Depicted are mean ± SEM 
for n = 8. *p < 0.05, and **p < 0.01 vs. Placebo.
After severe burn injury, estrogen significantly decreases the  local levels of IL-1β in the brain Figure 3
After severe burn injury, estrogen significantly 
decreases the local levels of IL-1  in the brain. At the 
0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hour time-points, there was a 
substantial decrease in the levels of IL-1β in the 17 β-estra-
diol treated group compared to placebo. Depicted are mean 
± SEM for n = 8. *p < 0.05, **p < 0.01, † p < 0.001 vs. Pla-
cebo.Journal of Neuroinflammation 2009, 6:30 http://www.jneuroinflammation.com/content/6/1/30
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the 24 hour time-point compared to the placebo and con-
trol groups (Fig. 5).
In prior burn studies, increased protein kinase B (Akt) sig-
naling has resulted in a decrease in apoptosis in peripheral
tissue, which has been identified as a major factor for cell
survival following injury [37,38]. In the current study, we
tested the hypothesis that estrogen increases the activity of
Akt in the brain after burn injury and we found that estro-
gen significantly (p < 0.05) increased the levels of phos-
pho-Akt by approximately 45 percent at 24 hours in the
rat brain after severe burn injury. In the placebo group,
there was no apparent increase in phospho-Akt levels
compared to the control group (Fig. 6).
Estrogen blocks caspase-3 activation and PARP 
inactivation after severe burn injury in rats
To determine if estrogen blocks caspase activation in our
burn model, we measured the levels of active caspase-3 in
the 24 hour rat brain samples. We found that at 24 hours
post-burn, the levels of active caspase-3 were unchanged
in the estrogen group compared with the control animals,
however there was a 2.5 fold increase in the levels of active
caspase-3 in the placebo group compared with the estro-
gen group (p < 0.01) (Fig. 7).
To determine whether caspase-3 activation leads to
increased apoptotic signaling in our burned animals, we
Estrogen treatment results in a decrease in IL-6 levels in the  brain following severe burn injury Figure 4
Estrogen treatment results in a decrease in IL-6 lev-
els in the brain following severe burn injury. After burn 
injury and subsequent estrogen treatment, using the ELISA 
assay, we found that at 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours 
post burn, there was a significant decrease (~90%) in the lev-
els of IL-6 in animals receiving 17 β-estradiol compared with 
the placebo group. Depicted are mean ± SEM for n = 8. † p < 
0.001, and ‡ p < 0.0001 vs. Placebo.
Estrogen treatment results in a significant increase in the lev- els of phospho-ERK, following severe burn injury Figure 5
Estrogen treatment results in a significant increase in 
the levels of phospho-ERK, following severe burn 
injury. Using Western blot analysis, we found that there was 
a significant increase in the levels of phospho-ERK in the 
estrogen treated group at 24 hours post burn. The ERK1 and 
2 blot displays equal loading between wells. Depicted are 
mean ± SEM for n = 5. *p < 0.01 vs. Placebo.
Following burn injury, estrogen treatment results in a signifi- cant increase in the levels of phospho-Akt Figure 6
Following burn injury, estrogen treatment results in 
a significant increase in the levels of phospho-Akt. As 
indicated by Western blot analysis, we determined that there 
was a significant increase in the levels of phospho-Akt in the 
estrogen treated group at 24 hours post burn. The ERK1 and 
2 blot displays equal loading between wells. Depicted are 
mean ± SEM for n = 6. *p < 0.05 vs. Placebo.Journal of Neuroinflammation 2009, 6:30 http://www.jneuroinflammation.com/content/6/1/30
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measured the levels of cleaved Poly (ADP-ribose)
Polymerase (PARP) from the brain tissues using Western
blot analysis. PARP is a nuclear enzyme that recognizes
and repairs damaged DNA. Following the initiation of
apoptosis, the activated caspases cleave the PARP enzyme
and block the repair of the DNA and cell survival [39-41].
The burned animals treated with estrogen exhibited low
levels of cleaved PARP that were similar to the control
group (p < 0.05), as opposed to a significant increase of
cleaved PARP seen in those animals treated with placebo
(Fig. 8).
Discussion
Abnormally high levels of circulating and tissue cytokines,
particularly IL-6, have been found to correlate with both
morbidity and mortality in patients with severe burn
injury [42-44]. In order to better explain these clinical
observations, models of acute severe burn injury in ani-
mals have demonstrated that secondary injury in the
periphery and central nervous system results in a disrup-
tion of both the metabolism and the activity of various
signaling pathways [10]. This secondary burn injury con-
sists, at least in part, of increased expression of pro-
inflammatory cytokines and increased cytokine signaling
[2-4]. Estrogen decreases this cytokine signaling by inter-
acting with transcription factors in a receptor-dependent
manner, and by decreasing the expression of cytokines
such as IL-6, IL-1β, and TNF-α. Upon binding to either
estrogen receptor (ER)-α or β, the resultant complex forms
a homo-dimer that then binds to transcription factors at
specific binding sequences. This binding blocks the ability
of the transcription factors to initiate the transcription of
numerous inflammatory cytokines [45-47]. In addition to
the classical estrogen receptors, a membrane ER may also
mediate the anti-inflammatory effects of estrogen follow-
ing burn injury [48].
Estrogen's ability to decrease the levels of pro-inflamma-
tory cytokines following severe burn injury may result in
significant protection in the brain. Therefore, as a first
investigative step, we chose to elucidate the early patterns
of inflammation and apoptosis in the brain following
severe burn injury, and to gauge the effects of estrogen on
these changes. In this study, severe burn injury resulted in
an extremely rapid and substantial increase in the levels of
TNF-α, IL-1β, and IL-6 in the rat brain tissue (Fig. 2, 3, 4).
We noted that in the estrogen treated group, the levels of
these pro-inflammatory cytokines were markedly sup-
pressed throughout all observed time-points, suggesting
that an acute dose of estrogen effectively suppresses burn-
induced surges in inflammatory cytokines in the brain.
Secondarily, we evaluated the MAPK in the brains of these
animals, to determine if the suppression of these
cytokines by estrogen might be mediated by ERK. In other
experimental models, estrogen administration has dem-
onstrated modulation of the activity of signaling path-
ways such as the mitogen activated protein kinase
(MAPK) within minutes of drug delivery. This effect of
estrogen on intra-cellular signaling pathways is non-
genomic, and leads to enhanced growth, cell survival, or
even cell death, depending on the activation kinetics of
the various signaling factors [49-57]. The activity of the
ERK has been found to be increased in the brain at 6 hours
Estrogen decreases the levels of activated caspase-3 after  severe burn injury Figure 7
Estrogen decreases the levels of activated caspase-3 
after severe burn injury. In these studies, we found that 
there was a significant decrease in the levels of activated cas-
pase-3 in the estrogen treated group at 24 hours post burn. 
The ERK1 and 2 blot displays equal loading between wells. 
Depicted are mean ± SEM for n = 6. *p < 0.01 vs. Placebo.
Estrogen blocks burn-induced PARP inactivation Figure 8
Estrogen blocks burn-induced PARP inactivation. 
Twenty four hours following burn injury and acute estrogen 
treatment, estrogen significantly blocked PARP cleavage. The 
ERK1 and 2 blot displays equal loading between wells. 
Depicted are mean ± SEM for n = 5. *p < 0.05 vs. Placebo.Journal of Neuroinflammation 2009, 6:30 http://www.jneuroinflammation.com/content/6/1/30
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following burn injury [5], demonstrating that following
burn injury, there are significant changes in the MAPK sig-
naling factors. Estrogen is known to activate the ERK path-
way to promote cell survival or growth [30,54], and
previous studies have shown that ERK blocks cytokine sig-
naling [58,59]. Thus, the marked increase of phospho-
ERK that we observed at the 24 hour time-point suggests
that ERK may be an important mediator of estrogen's pro-
tective actions in the brain following severe burn injury.
Based on our current findings, we believe that the estro-
gen-induced increase in ERK following burn injury results
in a decrease in cytokine signaling and subsequent
cytokine production. This decrease in inflammation could
translate into less damage and cell loss in the brain, which
may in the future be shown to preserve cognition in
patients with severe burn injury.
This study could not determine if the observed profound
increase in brain pro-inflammatory cytokines was due to
local brain synthesis or from peripherally produced
cytokines that penetrated into the brain. We believe that
the observed burn-induced increase in pro-inflammatory
cytokines was from local sources for two reasons. First, in
this study, plasma levels of TNF-α, IL-1β and IL-6, while
substantially increased following burn injury, were 10-
fold lower than levels that we detected in the brain (Wig-
ginton, JG et al., unpublished observation), suggesting
that brain transport of these peripherally-derived
cytokines against a concentration gradient is not likely.
Second, glia and neurons are well known sources of brain
cytokines and may be the source of local cytokine produc-
tion in the brain following severe burn injury [60,61]. Our
hypothesis that the elevated cytokine concentrations were
produced in the brain is also supported by previous stud-
ies, which have demonstrated increases in stress in the
brain as measured by electroencephalography following
severe burn injury of peripheral tissue. This increased
activity and brain inflammation is thought to be a result
of increased nitric oxide signaling, resulting in increased
production of inflammatory cytokines by astrocytes,
microglia, and neurons [15,62]. Elevations of nitric oxide
levels have been previously shown to increase inflamma-
tion and mortality following severe burn [63-65].
Because local accumulation of cytokines may induce
apoptosis and significantly extend the initial injury, we
also wanted to determine if estrogen's ability to block
cytokine signaling would lead to a decrease in the activa-
tion of apoptotic proteins in the brain. In previous stud-
ies, severe burn injuries have been associated with a
significant increase in apoptosis [5-9]. Here, we deter-
mined that estrogen administration following burn injury
increased the activity of Akt and decreased the levels of
active caspase-3. Akt is an anti-apoptotic factor that stabi-
lizes the mitochondria. This mitochondrial stabilization
is effected by decreasing cytochrome-C release (an initia-
tor of apoptosis) and decreasing caspase activation [66-
68]. As a result of these alterations, we noted a significant
decrease in PARP cleavage, indicating that apoptotic epi-
sodes are decreased in the estrogen-treated groups. These
studies support the idea that the brain undergoes early,
marked changes following remote burn injury, which may
be responsible for a dramatic increase in cell death and a
subsequent reduction in brain function.
While these studies are extremely provocative, there are
several limitations that should be addressed in future
investigations. First, while both sexes of animals have
been noted to benefit from early estrogen administration
in many models of injury, including stroke and hemor-
rhagic shock [69,70], we chose to study intact male ani-
mals to reduce or eliminate the effects of endogenous
estrogen and to focus solely on the effects of exogenous
estrogen following burn injury. With regard to estrogen
delivery, the subcutaneous route of administration in this
study produced considerably elevated estradiol levels as
early as 15 minutes post-administration, resulting in sig-
nificant cytokine reductions at all time points. However,
these elevations in circulating levels of estradiol were
delayed compared with prior estradiol pharmacokinetic
observations in the rodent model [35]. We hypothesize
that the delay in the peak of systemic estradiol levels may
be due to peripheral vasoconstriction following this large
burn injury, and the clinical relevance of the severe burn
injury model may be improved by intravenous adminis-
tration of the drug. Additionally, we chose to build on our
prior work by administering an extremely large burn to
these animals. The effects on the brain and the effects of
estrogen on smaller or larger injuries can only be hypoth-
esized based on the current data. In addition, these ani-
mals were only allowed to survive for 24 hours following
burn injury, as the nine time points observed in this study
afforded us the opportunity to elucidate the rapid and dra-
matic changes in the brain following severe burn injury.
While we structured this study to observe the pure, acute
effects of estrogen administration on burn injury, it may
be possible to improve the clinical significance of this ani-
mal model in future studies by increasing the survival
time of the animals, and by also noting estrogen's effects
on post-burn complications frequently seen in our clinical
patients. Finally, while markers of inflammation and
apoptosis are important and clinically relevant, future ani-
mal studies evaluating the changes in the rats' pre- and
post-burn cognitive function could further solidify our
current observations of estrogen's protective effects on the
brain following burn injury.
Despite these limitations, we conclude that following
severe burn injury in a rodent model, an early, single dose
of estrogen dramatically reduces brain inflammation andJournal of Neuroinflammation 2009, 6:30 http://www.jneuroinflammation.com/content/6/1/30
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apoptosis for up to 24 hours post-injury. While further
studies are warranted, it is our hope that results from these
studies will help guide the development of a safe, inex-
pensive, easy-to-deliver, and effective exciting new ther-
apy aimed at significantly improving the outcomes of
patients with severe burn injury in the near future.
In conclusion, we observed that estrogen treatment pro-
tects the brain through two main pathways following
severe burn injury in rats. In the first pathway, estrogen
increases the levels of phospho-Akt, which leads to a
decrease in caspase-3 activity and subsequent PARP cleav-
age, and ultimately protects the cell from increased pro-
grammed cell death. In a second pathway, we note that
estrogen reduces inflammation in the brain, most likely
by increasing ERK activation after burn injury. This
increase in ERK activation by estrogen might lead to
decreased cytokine signaling in cells and decreased brain
inflammation (Fig. 9). These results support the conclu-
sion that acute estrogen administration following severe
burn injury in rats reduces early brain inflammation and
apoptotic cell death.
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